Abstract: Objective To evaluate the clinical efficacy and safety of large dose of domestic interferon-α2b and ribavirin in the treatment of patients with chronic hepatitis C（CHC）. Methods In this study,we recruited 178 patients with CHC between January 2012 and January 2016,and 148 patients were treated with domestic interferon-α2b at dose of 6 MU qod in combination with ribavirin,and 30 patients were treated with pegylated interferon-α in combination with ribavirin. The regimen lasted for 48 weeks and all patients were followed-up for 24 weeks. Results At presentation,serum ALT level was （80.9±22.6）U/L,serum AST level was （74.3±18.2）U/L,and serum HCV RNA load was （2.9±0.5）×10⁵copies/mL in patients receiving domestic interferon-α,no significant differences as compared to 【（82.32± 20.5） U/L,（72.9±16.7）u/L and （2.8±0.5）×10⁵copies/ml】 in patients receiving pegylated interferon-α（P>0.05）;at the end of 4 w,12 w,24 w and 48 w treatment and at the end of 24 w followed-up,serum ALT normalization rats in domestic interferon-treated patients were 79.7%,87.2%,90.5%,92.6% and 86.5%,without significant differences as compared to 76.7%,83.3%,90.0%,93.3% and 90.0% in pegylated interferon-α-treated patients（P>0.05）;serum HCV RNA loss were 66.2%,71.0%,84.5%,90.5%and 69.5%,without significant differences as compared to 66.7%,73.3%,80.0%,90.0% and 70.0% in pegylated interferon-α-treated patients（P>0.05）;the hypocytosis,hair loss and anorexia were more common and severe in pegylated interferon-α-treated patients（P<0.05）. Conclusion The application of large -dose interferon α2b in combination with ribavirin in the treatment of patients with CHC might get the same clinical efficacy of pegylated interferon-α treatment,with less side effects, which needs further investigation and long-term observation.

Key words: Hepatitis C, Domestic interferon-α2b, Pegylated interferon, Treatment